Browse > Article

Activity of Moxifloxacin Against Ofloxacin-Resistant Mycobacterium Tuberculosis: A Study of Cross-Resistance Between Ofloxacin and Moxifloxacin  

Kim, Byoung Ju (Clinical Research Center for Tuberculosis, National Masan Hospital)
Kang, Young Soo (Clinical Research Center for Tuberculosis, National Masan Hospital)
Park, Seung Kyu (Clinical Research Center for Tuberculosis, National Masan Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.5, 2004 , pp. 405-410 More about this Journal
Abstract
Background : Moxifloxacin is an 8-methoxyquinolone compound which has been shown to have the best activity of the quinolones against M. tuberculosis but there is no literature showing the rate of cross-resistance between moxifloxacin and the other quinolones such as ofloxacin. Therefore, we tested the activity of moxifloxacin against ofloxacin resistant M. tuberculosis by a study of cross-resistance. Methods : We tested MIC's of moxifloxacin and ofloxacin by proportion method against 34 M. tuberculosis isolates showing resistance against ofloxacin at $2.5{\mu}g/m{\ell}$ concentration and 13 ofloxacin susceptible isolates from specimens submitted to clinical laboratory of National Masan Hospital from March 2003 to March 2004. Results : For ofloxacin susceptible isolates, $MIC_{50}$ and $MIC_{90}$ of ofloxacin were all $1.25{\mu}g/m{\ell}$, and $MIC_{50}$ and $MIC_{90}$ of moxifloxacin were $0.31{\mu}g/m{\ell}$ and $0.63{\mu}g/m{\ell}$ respectively. For ofloxacin resistant isolates, $MIC_{50}$ of ofloxacin was over $10{\mu}g/m{\ell}$ and $MIC_{50}$ of moxifloxacin was $5{\mu}g/m{\ell}$, $MIC_{90}$ of ofloxacin and moxifloxacin were all over $10{\mu}g/m{\ell}$. The rate of cross-resistance between the two was 67.6%(23/34) at $2.5{\mu}g/m{\ell}$ concentration. Conclusions : Moxifloxacin showed activity against 82.4%(28/34) of ofloxacin resistant M. tuberculosis at $10{\mu}g/m{\ell}$, but more studies are needed so that moxifloxacin will be used for patient with multi-drug resistant tuberculosis including oflokacin resistance.
Keywords
Moxifloxacin; Ofloxacin; Quinolone; Cross-resistance; Tuberculosis;
Citations & Related Records

Times Cited By SCOPUS : 2
연도 인용수 순위
1 Ravielione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6   DOI   ScienceOn
2 Yew WW, Piddock LJ, Li MB, Lyon D, Chan CY, Cheng AF. In-vitro activity of quinolones and macro lides against mycobacteria. J Antimicrob Chemother 1994;34:343-51   DOI   ScienceOn
3 Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-5   DOI
4 Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-71
5 Ginsbure AS, Woolwine SC, Hooper N, Benjamin WH Jr, Bishai WR, Dorman SE, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003;349:1977-8
6 Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, et al. In vitro acti vities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000;44:2567-8
7 Frieden TR, Sterline T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6   DOI   ScienceOn
8 Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Aeents 2002;20:464-7
9 Hu Y, Coates AR, Mitchison DA. Sterilizine activities of fluoroquinolones against rifampin-tolerant popul ations of Mycobctcterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-7
10 Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest 1999;17:365-87
11 Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50
12 Yamane N, Chilima BZ, Tosaka M, Okazawa Y, Tanno K. Determination of antimycobacterial acti vities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media. Kekkaku 1996;71:453-8
13 Lee HS, Kang YA, Oh JY, Lee JH, Yoo CG, Lee CT, et al. A case of pulmonary tuberculosis with delayed diagnosis due to the temporary clinical improvement after use of levofloxacin and amikacin under the impression of community acquired pneumonia. Tuberc Respir Dis 2003;55:395-401
14 Culliton BJ. Drug-resistant TB may bring epidemic. Nature 1992;356:473
15 Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bon nafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9
16 Goble M, Iseman MD, Madsen LA, Waite D, Acker son L, Horsbergh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isomazid and rifampin. N Engl J Med 1993;328:527-32   DOI   ScienceOn
17 Hoffner SE, Gezelius L, Olsson-Liljegaist B. In-vitro activity of fluorinated quinolones and macrolides against durg-resistant Mycobacterium tuberculosis. J antimicrob Chemother 1997;40:885-8   DOI   ScienceOn
18 Xa C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996;174:1127-30